Celyad Oncology SA

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. -3.47%75.740.0%$2401.32m
NVAXNovavax, Inc. 10.46%173.6299.2%$1289.10m
GILDGilead Sciences, Inc. -2.48%69.121.0%$526.68m
AMGNAmgen, Inc. -1.02%241.101.3%$510.35m
REGNRegeneron Pharmaceuticals, Inc. -3.55%625.412.5%$458.70m
SRNESorrento Therapeutics, Inc. 7.09%13.751.8%$446.81m
BNTXBioNTech SE -2.38%81.190.0%$403.05m
VRTXVertex Pharmaceuticals, Inc. -1.31%272.091.9%$379.53m
BIIBBiogen, Inc. -0.14%275.701.6%$326.48m
ILMNIllumina, Inc. 1.87%401.033.5%$325.92m
VXRTVaxart, Inc. 8.71%9.670.0%$325.47m
IBIOiBio, Inc. -0.46%4.371.8%$181.81m
EBSEmergent BioSolutions, Inc. 9.50%134.286.4%$177.19m
SGENSeattle Genetics, Inc. -1.67%162.326.1%$172.19m
ALXNAlexion Pharmaceuticals, Inc. -2.29%102.812.0%$170.96m

Company Profile

Celyad SA is a clinical-stage biopharmaceutical company, which engages in the development of cell-based therapies for the treatment of cancer. It operates through the following segments: Cardiology, Immuno-oncology, and Corporate. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.